We are live on ! Find out more

Cencora

COR

Market cap $61.9B

324.24 USD

-0.45

0.14%

At close Updated Sep 9, 9:44 AM EDT

1 day

-0.14%

5 days

-1.93%

1 month

-0.23%

3 months

15.98%

6 months

-10.38%

Year to date

-4.32%

1 year

8.56%

5 years

162.33%

10 years

280.07%

About: Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

Employees: 51,000

Healthcare Medical Distribution

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 58.5%

Neutral 34.1%

Negative 7.3%

Cencora, Inc. (COR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Cencora, Inc. (COR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Cencora, Inc. (COR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Zacks Investment Research

Why Cencora (COR) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Cencora (COR) is a Top Growth Stock for the Long-Term

Zacks Investment Research

Here's Why You Should Retain Cencora Stock in Your Portfolio for Now

Cencora's specialty momentum, OneOncology growth and GLP-1 volumes offer upside, but drug-price cuts and MWI risks cloud its outlook.

Here's Why You Should Retain Cencora Stock in Your Portfolio for Now

Zacks Investment Research

Cencora (COR) Up 3.8% Since Last Earnings Report: Can It Continue?

Cencora (COR) reported earnings 30 days ago. What's next for the stock?

Cencora (COR) Up 3.8% Since Last Earnings Report: Can It Continue?

Zacks Investment Research

Cencora Launches Cell and Gene Therapy Enablement for Health Systems

COR launches CGT Enablement to help health systems build and scale cell and gene therapy programs with financial, operational and access support.

Cencora Launches Cell and Gene Therapy Enablement for Health Systems

Zacks Investment Research

Cencora Raises 2026 EPS Outlook as Specialty Businesses Strengthen

Cencora raised its fiscal 2026 EPS outlook as specialty businesses fueled stronger profit growth despite mix, pricing and financing pressures.

Cencora Raises 2026 EPS Outlook as Specialty Businesses Strengthen

Cencora's Accelerate Pharmacy Solutions Launches Cell and Gene Therapy Enablement to Help Health Systems Build and Scale Programs

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora today launched a service to help health systems evaluate, build and scale cell and gene therapy (CGT) programs. Offered through Accelerate Pharmacy Solutions, Cell and Gene Therapy Enablement is designed to help health systems strengthen operational readiness and program execution to reduce barriers to care and expand patient access to advanced therapies. “Cell and gene therapies have the potential to transform care for patients with serious and compl.

Cencora's Accelerate Pharmacy Solutions Launches Cell and Gene Therapy Enablement to Help Health Systems Build and Scale Programs

Invesco Discovery Mid Cap Growth Fund Q2 2026 Portfolio Performance

Invesco Discovery Mid Cap Growth Fund had a positive return and outperformed its benchmark in the second quarter. The fund was underweight in the communication services, health care and consumer discretionary sectors. Strong stock selection and an overweight in IT added to relative return. Weakness in energy partially offset the favorable results.

Invesco Discovery Mid Cap Growth Fund Q2 2026 Portfolio Performance

Artisan Global Opportunities Fund Q2 2026 Portfolio Review

During the quarter, we initiated positions in GE Aerospace, Corning, STMicroelectronics and Robinhood. Notable adds during the quarter included DoorDash and Keyence. We ended our investment campaigns in Cencora, Lonza Group and Medline during the quarter.

Artisan Global Opportunities Fund Q2 2026 Portfolio Review

Zacks Investment Research

Why Cencora (COR) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Cencora (COR) is a Top Value Stock for the Long-Term

See News Rankings

Price charts implemented using Lightweight Charts™